The European Commission Has Approved Mirati Therapeutics' Krazati (Adagrasib) For KRASG12C-mutated Advanced Non-small Cell Lung Cancer And Disease Progression After At Least One Prior Systemic Therapy
Author: Benzinga Newsdesk | January 10, 2024 09:04am